GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology A

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American Society of Hematology (ASH) Annual Meeting will feature two presentations o...

Related Keywords

Australia ,Baylor College Of Medicine ,Texas ,United States ,Houston ,Rockville ,New Zealand General ,New Zealand ,China ,Edwin Rock ,Queensland ,America ,Chinese ,American ,Emmanuel Almanza Huante ,Micheles Redell ,Leo Vartorella ,San Diego Convention Center ,Company Annual Report On Form ,Glycomimetics Inc ,Nasdaq ,Leukemia Lymphoma Society ,Exchange Commission ,Chinese National Medical Products Administration ,Drug Administration ,Department Of Leukemia ,American Society Of Hematology ,University Of Texas Md Anderson Cancer Center ,Texas Children Cancer Center ,National Cancer Institute ,American Society ,Annual Meeting ,Acute Myeloid Leukemia ,Chief Medical Officer ,Cladribine Plus Low Dose Cytarabine ,Treated Secondary Acute Myeloid Leukemia ,Cancer Center ,Myeloid Leukemias ,Investigational Therapies ,Excluding Transplantation ,Hallsg H ,Acute Leukemia ,Screening Trial ,Developing New Therapies ,Relapsed Leukemias ,Texas Children ,Baylor College ,Lymphoma Society ,North America ,Breakthrough Therapy ,Fast Track ,Biohealth Capital ,Annual Report ,